Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Pohl's vision on 10/2/06

Pohl's vision on 10/2/06

posted on Jan 15, 2008 09:51AM

TWST: What would you reasonably expect the company

to look like in about three years? What might be some milestones

along the way for potential investors to note?

Mr. Pohl:
To date, over 300 companies have been put on

notice for the fact that they are possibly infringing. That should give

investors some sense of the size of the potential pipeline of licensing

candidates that is out there, and we currently can point with pride to

10 licenses in total. That means there are a lot more to come. So the

answer to your question is that three years from now, I picture this

company as being one that has capitalized on the opportunity to accumulate

some impressive amounts of cash in the form of licensing

revenues. Milestones would possibly include that the Board of Directors

might decide to pay some dividends to shareholders along the

way. In addition to that, the company will definitely have taken a

look at adding additional revenue streams through acquisition opportunities

and perhaps the opportunity to acquire additional technology.

So I would see this company three years from now, barring any unforeseen

developments, as being a financially strong company, listed

on a major stock exchange, and one with income and growth potential

as a very attractive investment for shareholders.

Share
New Message
Please login to post a reply